Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 study of HSK44459 in progressive pulmonary fibrosis
CTR20261792Phase 3Active
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- May 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of HSK44459 in pulmonary fibrosis (PF), sponsored by Haisco Pharmaceutical Group Co., Ltd.. Started May 2026; status: active.
02
Drugs
HSK44459
03
Conditions
pulmonary fibrosis (PF)
Beyond the preview
Go deeper on CTR20261792.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20261792.